Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of PCSK9 Inhibitor on Retinal Microvessels in Patients With Coronary Heart Disease
NCT05802108Phase 4Unknown
- Sponsor
- Zibo City Central Hospital
- Start
- Jul 2022
- Primary completion
- Jun 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of evolocumab in coronary heart disease (CHD), sponsored by Zibo City Central Hospital. Status: unknown.
02
Drugs
evolocumab
03
Conditions
coronary heart disease (CHD)
Beyond the preview
Go deeper on NCT05802108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05802108.